Human papillomavirus (HPV) continues to pose a significant global public health challenge, linked to various health risks such as cervical cancer and other malignancies. This comprehensive review explores diverse facets of HPV, including its types, transmission, associated risk factors, causes, and treatment strategies. The objectives encompass a detailed examination of HPV's etiology, current treatment modalities, market trends, and broader public health implications. The review critically evaluates the efficacy and safety profiles of existing HPV treatments, emphasizing the adverse drug reactions (ADRs) associated with each approach. Moreover, the review proposes an innovative treatment strategy involving a combination of polyethylene glycol (PEG) and pyrazomycin as a potential alternative to conventional therapies. This approach is grounded in the structural similarities between pyrazomycin and ribavirin, suggesting potential efficacy in HPV treatment. Drawing on supportive evidence from the literature, the review underscores pyrazomycin's antiviral properties and its compatibility with PEG, highlighting the need for further research into this promising treatment avenue. In conclusion, the review advocates for informed decision-making in healthcare practices and public health policy, presenting new avenues for improving HPV care through exploration of alternative treatment strategies.